33° Sunny

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition
STOCKING STUFFER CONTEST

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

10.01 +0.55 (+5.81%)

Streaming Delayed Price Updated: 10:03 AM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship ↗

April 13, 2022

Flagship Pioneering is swiping one of AbbVie's biggest names.

Via Investor's Business Daily

Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

April 06, 2022

On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago.

Via Investor's Business Daily

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

Where Biohaven Pharma Hldgs Stands With Analysts ↗

January 07, 2022

Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN...

Via Benzinga

Analyst Ratings For Biohaven Pharma Hldgs ↗

October 19, 2021

Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the f...

Via Benzinga

Biohaven Pharmaceutical's Return On Capital Employed Insights ↗

February 28, 2022

Biohaven Pharmaceutical (NYSE:BHVN) brought in sales totaling $190.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 15.81%, resulting...

Via Benzinga

Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals ↗

February 25, 2022

Biohaven inked a pair of deals that one analyst find promising for its pipeline.

Via Investor's Business Daily

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals ↗

February 25, 2022

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY) to...

Via Benzinga

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision ↗

February 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To...

Via Benzinga

Biohaven Pharma: Q4 Earnings Insights ↗

February 25, 2022

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM. Here's what investors need to know about the announcement....

Via Benzinga

Earnings Scheduled For February 25, 2022 ↗

February 25, 2022

Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •...

Via Benzinga

Biohaven Pharmaceutical's Earnings Outlook ↗

February 24, 2022

Biohaven Pharmaceutical (NYSE:BHVN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints ↗

February 14, 2022

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) reported topline results from an Asia-Pacific, Phase 3 trial of...

Via Benzinga

New Psychedelics ETF Launches On NYSE Arca ↗

February 02, 2022

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...

Via Benzinga

This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut ↗

January 20, 2022

John Chiminski knows he doesn't fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change.

Via Investor's Business Daily

2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)

January 06, 2022

Via AB Newswire

The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales ↗

January 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating...

Via Benzinga

Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial ↗

December 06, 2021

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its...

Via Benzinga

What 6 Analyst Ratings Have To Say About Biohaven Pharma Hldgs ↗

November 10, 2021

Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the ...

Via Benzinga

75 Biggest Movers From Yesterday ↗

November 10, 2021

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers...

Via Benzinga

Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M ↗

November 09, 2021

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S....

Via Benzinga

58 Stocks Moving In Monday's Mid-Day Session ↗

November 09, 2021

Gainers Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash. TDH...

Via Benzinga

Why Biohaven Pharmaceuticals Stock Crumbled On This Premium Deal With Pfizer ↗

November 09, 2021

Biohaven will receive up to $1.24 billion in payments under a deal for Nurtec ODT.

Via Investor's Business Daily

Jim Cramer: MGM Resorts Has Good Top Management ↗

November 09, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said MGM Resorts International (NYSE: MGM) has a lot of good top management. With Wynn Resorts, Limited (NASDAQ...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 09, 2021

Gainers Compass Pathways (NASDAQ:CMPS) shares rose 18.43% to $51.0 during Tuesday's pre-market session. The company's market cap stands at $2.1 billion. As per the...

Via Benzinga

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Cramer Likes American Eagle Outfitters And These 2 Pharma Stocks ↗

October 18, 2021

On CNBC’s “

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Biohaven Ltd. Common Shares (NY:BHVN)

All News about Biohaven Ltd. Common Shares

Sections

Services